Sarissa knew this drug was coming out and knew it would be high cost and positioned Vascepa to get used. The Fibrate market label change was part of it. Vascepa is a cheaper drug that works and this new drug has no reimbursement models. The PBM will shunt to Vascepa, not Fibrates or this new costly drug. Tier placement matters. Now factor in an authorized generic and a new patent.
Market Data 
Markets 
AI
